Sermorelin + Ipamorelin (Compounded GH Blend)

Sermorelin + ipamorelin is the growth hormone blend many clinics reach for first. It is usually dispensed as a single premixed vial labeled 'sermorelin/ipamorelin' and injected under the skin at bedtime. The pitch is simple: two peptides that each tell the pituitary to release growth hormone (GH), acting through two different receptors, so the combined GH pulse is bigger than either peptide alone produces. Clinics market it for better sleep, recovery, body composition, and 'healthy aging'. Each half was chosen for a reason. Sermorelin is the first 29 amino acids of human growth hormone-releasing hormone (GHRH), the shortest fragment with full activity. Its main selling point is its history. Serono sold it as Geref, which the FDA approved as a diagnostic test for GH reserve in 1990 and as a treatment for children with GH deficiency in 1997. EMD Serono discontinued the products in 2008, and in 2013 the FDA formally determined they were not withdrawn for reasons of safety or effectiveness. That makes sermorelin the only peptide in this class with a past FDA approval behind it. Ipamorelin is a five-amino-acid ghrelin-receptor agonist developed by Novo Nordisk in the late 1990s. It was selected for selectivity: in the original swine studies, GHRP-6 and GHRP-2 raised ACTH and cortisol along with GH, while ipamorelin did not, even at doses more than 200-fold above its effective GH-releasing dose. How it differs from the other GH stacks on this site: CJC-1295 + ipamorelin uses the same ghrelin-side partner but a different GHRH leg. CJC-1295 is a modified GHRH engineered to last longer. The 'with DAC' version binds albumin and keeps GH and IGF-1 raised for days after one dose. The 'no DAC' version (Mod GRF 1-29) is essentially sermorelin with four amino-acid substitutions that slow its breakdown. Sermorelin is the unmodified sequence: it clears within minutes and produces one discrete pulse per injection. CJC-1295 has never been approved anywhere, and its 503A compounding nominations were withdrawn. Sermorelin's approval history gives it a sturdier compounding footing. Sermorelin + glycine is a single-peptide formulation, usually a dissolving troche, that pairs sermorelin with the amino acid glycine for sleep. It has no ghrelin-receptor component, so it doesn't attempt the two-receptor synergy at all. Sermorelin + ipamorelin is the injectable, two-mechanism version. Tesamorelin + ipamorelin swaps in the one GHRH analog that is currently FDA-approved (for HIV-associated belly fat). Same logic, different GHRH leg, different regulatory and evidence profile.

GH release from the pituitary is driven by two stimulating signals, with somatostatin acting as the brake. GHRH binds its receptor on somatotroph cells and raises cAMP, which increases GH production and sets how big the next pulse can be. Ghrelin, and drugs that mimic it, bind a separate receptor (GHS-R1a) and trigger release through a different intracellular pathway (PLC/IP3/PKC). Sermorelin supplies the first signal. Ipamorelin supplies the second. The synergy between the two signals is established human physiology, not marketing. In 1990, Bowers and colleagues gave healthy men the GH-releasing peptide GHRP-6 together with GHRH and found the combined GH response was synergistic, meaning larger than the two responses added together. Hataya and colleagues showed the same thing in 2001 with low-dose ghrelin itself plus GHRH, and suggested the pairing could serve as a diagnostic test for GH deficiency. Bowers' group concluded the two act independently, which is why combining them amplifies the pulse. The mechanism behind sermorelin + ipamorelin is sound. Two features of this particular pair shape what it can and can't do. First, both peptides are short-acting. Sermorelin is cleared by DPP-4 and other peptidases within minutes, and ipamorelin's half-life in healthy volunteers was about two hours. Injected together, they produce one amplified pulse that then clears. That preserves the normal on-off pattern of GH secretion and leaves IGF-1 feedback intact, which is the main safety argument for secretagogues over injected GH. It also means the effect has a ceiling: the response depends on how much GH the pituitary can make, and is blunted by obesity, high insulin, a recent meal, and age. Second, more is not better. GH release from both peptide classes follows a bell-shaped dose response, so higher doses run into a ceiling rather than producing a proportionally bigger pulse. Fixed-ratio premixed vials also mean the two components can't be adjusted independently.

The synergy evidence is physiology, not outcomes. The Bowers (1990) and Hataya (2001) studies gave single intravenous doses of GHRH(1-44) with GHRP-6 or native ghrelin and measured GH over a few hours. They did not test sermorelin with ipamorelin, did not use under-the-skin dosing, and did not measure IGF-1, body composition, sleep, or anything a patient would feel. They establish that the two pathways cooperate. They do not establish that this blend produces clinical benefits. Sermorelin has real clinical data, mostly in children and mostly old. The Geref International Study Group showed once-daily sermorelin accelerated growth in GH-deficient children over the first year of treatment. Adult data are small and short. In older men, 1 mg twice daily for 14 days restored GH and IGF-1 to young-adult levels, but a 0.5 mg twice-daily dose did not reach significance (Corpas et al., 1992). In a 6-week study, a single nightly 2 mg injection in healthy elderly men raised nocturnal GH but did not raise IGF-1 or change body composition. The authors concluded that single nightly doses are less effective than multiple daily doses (Vittone et al., 1997). That finding matters here: the typical clinic protocol is a single bedtime injection at a fraction of 2 mg. Ipamorelin's human evidence is thinner. Its selectivity profile comes from animal studies (Raun et al., 1998), and a human pharmacokinetic study confirmed a dose-proportional, single GH pulse after intravenous infusion. Its only completed Phase 2 efficacy trial was in a different indication: postoperative ileus after bowel surgery. In that trial of 117 patients (Beck et al., 2014), intravenous ipamorelin did not significantly shorten time to first tolerated meal versus placebo (median 25.3 vs 32.6 hours, p=0.15), with no significant differences on secondary endpoints. The program did not advance. Ipamorelin has never been tested in a controlled trial for body composition, sleep, or aging. The combination itself has no published trial of any kind: no IGF-1 dose-finding, no body-composition study, no sleep study. Claims about 'sermorelin ipamorelin results' come from clinic marketing and user reports, not controlled data. The honest summary: a mechanistically sound pairing of one well-characterized peptide and one thinly characterized peptide, with zero direct evidence for the outcomes it is sold for.

There is no validated protocol for this combination. What follows is what is commonly discussed in clinic and community settings, not a recommendation. The blend is usually injected subcutaneously at bedtime, on an empty stomach (at least two hours after the last meal), to line up with the body's natural overnight GH pulse and avoid the blunting effect of insulin. Commonly discussed amounts run roughly 200–500 mcg of sermorelin with 200–300 mcg of ipamorelin per injection, nightly or five nights a week. Courses of 3–6 months are commonly described, sometimes with breaks, though no trial supports any particular cycle length. Some protocols add a morning dose. The older-adult studies that moved IGF-1 used higher doses or twice-daily dosing, so a single low bedtime dose may do less than marketing suggests. Any use should be supervised by a qualified clinician who checks baseline IGF-1, fasting glucose or HbA1c, and thyroid status, rechecks IGF-1 at roughly 8–12 weeks, and stops or adjusts if IGF-1 climbs above the age-appropriate range. If IGF-1 doesn't move after a few months, the likely explanations are product quality, dose timing, or limited pituitary reserve, not a need for more peptide.